This patent filing is a minor positive for IP positioning but does not change the company's near-term outlook. Monitor for clinical trial updates or financing events, as the company has a $2M market cap and likely needs capital.
Price Chart
Executive Summary
Clearmind Medicine announced the publication of a Japanese patent application for its MEAI-based depression treatment, expanding its global IP portfolio. This is a routine IP development for a clinical-stage biotech with no revenue, and the filing does not contain financial data or near-term catalysts.
Key Facts
- Japanese patent application published for MEAI compositions to treat depression.
- MEAI is Clearmind's flagship non-hallucinogenic molecule.
- Company's IP portfolio includes 19 patent families and 31 granted patents.
- No financial data, clinical trial results, or guidance provided in the filing.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company.
Risk Factors
- Patent issuance is not guaranteed and may not be commercially advantageous.
- No revenue or near-term catalysts; high cash burn risk for a $2M market cap company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-062449 |
| Document: ea029271701ex99-1.htm | 0001213900-26-062449 |
| Document: 0001213900-26-062449-index-headers.html | 0001213900-26-062449 |
| Document: 0001213900-26-062449-index.html | 0001213900-26-062449 |
| Document: 0001213900-26-062449.txt | 0001213900-26-062449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $6.10 | awaiting T+60 | — | $5.97 (−2.10%) |
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.79%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers